Estuary Biotherapeutics has launched as a biotechnology company focused on genetic medicines for serious kidney diseases, backed by US$103 million in total committed financing. Its US$93 million Series A was led by RA Capital Management, with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, and the National Kidney Foundation Innovation Fund. The company will use proceeds to advance two lead programs, EST-201 and EST-101, through clinical proof of concept and expand its kidney-targeting platform.
Financing Details and Investor Backing
The Series A round also included a family office connected to an individual living with autosomal dominant polycystic kidney disease, or ADPKD. 4BIO Capital and GV, which co-led the company's US$10 million Seed financing, participated in the Series A as well. The funding syndicate reflects confidence in Estuary's potential to address the root cause of ADPKD with locally delivered gene therapies.
Scientific Foundation and Lead Programs
Estuary's approach builds on research from scientific co-founders Dr. Stefan Somlo and Dr. Michael Caplan of Yale School of Medicine. Dr. Somlo demonstrated that restoring polycystin expression in kidneys with established cystic disease can reverse structural and functional hallmarks of disease in mice. Dr. Caplan showed that a compact functional region of the polycystin-1 protein is sufficient to suppress cystic disease, supporting an AAV-based approach for ADPKD-PKD1.
Programs Targeting PKD1 and PKD2 Mutations
The company is advancing two locally delivered genetic medicines for ADPKD. EST-201 is a full-length PKD2 gene therapy delivered through AAV that is expected to enter the clinic in 2027 for patients with PKD2 mutations. EST-101 delivers a PC1-derived functional region via the same AAV and is anticipated to enter the clinic in 2028 for patients with PKD1 mutations.
Addressing a Significant Unmet Need
ADPKD is the most common inherited kidney disease, affecting more than 8 million people worldwide and representing the fourth most common cause of kidney replacement therapy globally. More than 90% of patients have mutations in PKD1 or PKD2, which lead to progressive cyst growth and eventual end-stage kidney disease. In the United States, rapidly progressing patient populations include approximately 10,000 to 15,000 people with PKD2 mutations and 100,000 to 140,000 people with PKD1 mutations.
Differentiated Delivery Strategy and Platform
Unlike systemic AAV gene therapies, Estuary's kidney-confined approach is designed to deliver genetic material directly to kidney epithelial cells. The goal is to restore polycystin protein levels across the entire nephron with a potentially one-time treatment. This strategy may avoid many risk-benefit challenges that have complicated systemically delivered AAV therapies to date.
Leadership and Future Plans
Estuary is led by a mission-driven team combining genetic medicine, kidney biology, and drug development expertise, with Wayne Sackett as co-founder and CEO. The board and advisors include veterans from Spark Therapeutics, REGENXBIO, and Sanofi, among others. Beyond its lead programs, Estuary plans to expand its pipeline to target both monogenic and common kidney diseases.
With a strong financing syndicate, a differentiated local delivery platform, and clinical timelines set for 2027 and 2028, Estuary Biotherapeutics is positioned to advance a new class of genetic medicines for ADPKD. The company's lead programs aim to treat the underlying genetic cause rather than downstream pathways, potentially halting or reversing disease progression. If successful, this approach could transform care for millions of patients living with one of the world's most common genetic diseases.